![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: XRN2 |
Gene summary for XRN2 |
![]() |
Gene information | Species | Human | Gene symbol | XRN2 | Gene ID | 22803 |
Gene name | 5'-3' exoribonuclease 2 | |
Gene Alias | XRN2 | |
Cytomap | 20p11.22 | |
Gene Type | protein-coding | GO ID | GO:0000003 | UniProtAcc | B4DZC3 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
22803 | XRN2 | LZE2T | Human | Esophagus | ESCC | 7.58e-08 | 1.24e+00 | 0.082 |
22803 | XRN2 | LZE4T | Human | Esophagus | ESCC | 2.86e-27 | 1.10e+00 | 0.0811 |
22803 | XRN2 | LZE5T | Human | Esophagus | ESCC | 4.21e-02 | 5.94e-01 | 0.0514 |
22803 | XRN2 | LZE7T | Human | Esophagus | ESCC | 1.21e-04 | 8.03e-01 | 0.0667 |
22803 | XRN2 | LZE8T | Human | Esophagus | ESCC | 6.04e-09 | 4.19e-01 | 0.067 |
22803 | XRN2 | LZE22D1 | Human | Esophagus | HGIN | 1.18e-02 | 8.68e-03 | 0.0595 |
22803 | XRN2 | LZE22T | Human | Esophagus | ESCC | 1.86e-05 | 5.00e-01 | 0.068 |
22803 | XRN2 | LZE24T | Human | Esophagus | ESCC | 3.24e-13 | 4.61e-01 | 0.0596 |
22803 | XRN2 | LZE21T | Human | Esophagus | ESCC | 2.16e-04 | 2.49e-01 | 0.0655 |
22803 | XRN2 | LZE6T | Human | Esophagus | ESCC | 6.68e-06 | 5.08e-01 | 0.0845 |
22803 | XRN2 | P1T-E | Human | Esophagus | ESCC | 4.51e-09 | 7.57e-01 | 0.0875 |
22803 | XRN2 | P2T-E | Human | Esophagus | ESCC | 3.22e-63 | 1.39e+00 | 0.1177 |
22803 | XRN2 | P4T-E | Human | Esophagus | ESCC | 4.50e-32 | 1.02e+00 | 0.1323 |
22803 | XRN2 | P5T-E | Human | Esophagus | ESCC | 1.45e-15 | 6.31e-01 | 0.1327 |
22803 | XRN2 | P8T-E | Human | Esophagus | ESCC | 6.66e-32 | 8.54e-01 | 0.0889 |
22803 | XRN2 | P9T-E | Human | Esophagus | ESCC | 4.30e-29 | 8.42e-01 | 0.1131 |
22803 | XRN2 | P10T-E | Human | Esophagus | ESCC | 2.63e-72 | 1.61e+00 | 0.116 |
22803 | XRN2 | P11T-E | Human | Esophagus | ESCC | 3.71e-15 | 9.41e-01 | 0.1426 |
22803 | XRN2 | P12T-E | Human | Esophagus | ESCC | 1.19e-43 | 1.40e+00 | 0.1122 |
22803 | XRN2 | P15T-E | Human | Esophagus | ESCC | 6.57e-57 | 1.42e+00 | 0.1149 |
Page: 1 2 3 4 5 6 7 |
![]() |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:0090503 | Liver | Cirrhotic | RNA phosphodiester bond hydrolysis, exonucleolytic | 19/4634 | 42/18723 | 3.00e-03 | 1.71e-02 | 19 |
GO:002261322 | Liver | HCC | ribonucleoprotein complex biogenesis | 355/7958 | 463/18723 | 7.76e-52 | 4.92e-48 | 355 |
GO:004225422 | Liver | HCC | ribosome biogenesis | 246/7958 | 299/18723 | 4.99e-46 | 1.58e-42 | 246 |
GO:00344702 | Liver | HCC | ncRNA processing | 293/7958 | 395/18723 | 4.26e-38 | 6.76e-35 | 293 |
GO:001607212 | Liver | HCC | rRNA metabolic process | 193/7958 | 236/18723 | 1.26e-35 | 1.14e-32 | 193 |
GO:000636421 | Liver | HCC | rRNA processing | 185/7958 | 225/18723 | 8.14e-35 | 6.45e-32 | 185 |
GO:00346601 | Liver | HCC | ncRNA metabolic process | 332/7958 | 485/18723 | 1.48e-31 | 7.80e-29 | 332 |
GO:004427021 | Liver | HCC | cellular nitrogen compound catabolic process | 303/7958 | 451/18723 | 9.76e-27 | 3.64e-24 | 303 |
GO:004670021 | Liver | HCC | heterocycle catabolic process | 299/7958 | 445/18723 | 2.07e-26 | 7.29e-24 | 299 |
GO:190136121 | Liver | HCC | organic cyclic compound catabolic process | 325/7958 | 495/18723 | 6.52e-26 | 2.18e-23 | 325 |
GO:001943921 | Liver | HCC | aromatic compound catabolic process | 309/7958 | 467/18723 | 1.56e-25 | 4.94e-23 | 309 |
GO:000640121 | Liver | HCC | RNA catabolic process | 201/7958 | 278/18723 | 3.88e-24 | 1.02e-21 | 201 |
GO:003465521 | Liver | HCC | nucleobase-containing compound catabolic process | 273/7958 | 407/18723 | 4.84e-24 | 1.23e-21 | 273 |
GO:000640221 | Liver | HCC | mRNA catabolic process | 169/7958 | 232/18723 | 4.50e-21 | 6.96e-19 | 169 |
GO:000095621 | Liver | HCC | nuclear-transcribed mRNA catabolic process | 84/7958 | 112/18723 | 2.54e-12 | 1.18e-10 | 84 |
GO:00905011 | Liver | HCC | RNA phosphodiester bond hydrolysis | 101/7958 | 152/18723 | 1.99e-09 | 5.63e-08 | 101 |
GO:0090305 | Liver | HCC | nucleic acid phosphodiester bond hydrolysis | 152/7958 | 261/18723 | 1.90e-07 | 3.46e-06 | 152 |
GO:00905031 | Liver | HCC | RNA phosphodiester bond hydrolysis, exonucleolytic | 29/7958 | 42/18723 | 4.57e-04 | 3.04e-03 | 29 |
GO:002261320 | Oral cavity | OSCC | ribonucleoprotein complex biogenesis | 333/7305 | 463/18723 | 8.28e-48 | 5.24e-44 | 333 |
GO:004225420 | Oral cavity | OSCC | ribosome biogenesis | 230/7305 | 299/18723 | 3.22e-41 | 6.80e-38 | 230 |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa0301810 | Esophagus | HGIN | RNA degradation | 27/1383 | 79/8465 | 7.73e-05 | 9.00e-04 | 7.15e-04 | 27 |
hsa0301815 | Esophagus | HGIN | RNA degradation | 27/1383 | 79/8465 | 7.73e-05 | 9.00e-04 | 7.15e-04 | 27 |
hsa0301824 | Esophagus | ESCC | RNA degradation | 62/4205 | 79/8465 | 1.18e-07 | 9.39e-07 | 4.81e-07 | 62 |
hsa0301834 | Esophagus | ESCC | RNA degradation | 62/4205 | 79/8465 | 1.18e-07 | 9.39e-07 | 4.81e-07 | 62 |
hsa03018 | Liver | Cirrhotic | RNA degradation | 44/2530 | 79/8465 | 1.43e-06 | 1.65e-05 | 1.02e-05 | 44 |
hsa030181 | Liver | Cirrhotic | RNA degradation | 44/2530 | 79/8465 | 1.43e-06 | 1.65e-05 | 1.02e-05 | 44 |
hsa030182 | Liver | HCC | RNA degradation | 58/4020 | 79/8465 | 2.29e-06 | 2.19e-05 | 1.22e-05 | 58 |
hsa030183 | Liver | HCC | RNA degradation | 58/4020 | 79/8465 | 2.29e-06 | 2.19e-05 | 1.22e-05 | 58 |
hsa030189 | Oral cavity | OSCC | RNA degradation | 59/3704 | 79/8465 | 2.05e-08 | 1.91e-07 | 9.70e-08 | 59 |
hsa0301814 | Oral cavity | OSCC | RNA degradation | 59/3704 | 79/8465 | 2.05e-08 | 1.91e-07 | 9.70e-08 | 59 |
hsa0301823 | Oral cavity | LP | RNA degradation | 39/2418 | 79/8465 | 6.98e-05 | 4.38e-04 | 2.83e-04 | 39 |
hsa0301833 | Oral cavity | LP | RNA degradation | 39/2418 | 79/8465 | 6.98e-05 | 4.38e-04 | 2.83e-04 | 39 |
hsa0301841 | Oral cavity | EOLP | RNA degradation | 22/1218 | 79/8465 | 1.33e-03 | 4.80e-03 | 2.83e-03 | 22 |
hsa0301851 | Oral cavity | EOLP | RNA degradation | 22/1218 | 79/8465 | 1.33e-03 | 4.80e-03 | 2.83e-03 | 22 |
hsa0301861 | Oral cavity | NEOLP | RNA degradation | 18/1112 | 79/8465 | 1.25e-02 | 4.06e-02 | 2.56e-02 | 18 |
hsa0301871 | Oral cavity | NEOLP | RNA degradation | 18/1112 | 79/8465 | 1.25e-02 | 4.06e-02 | 2.56e-02 | 18 |
hsa030188 | Prostate | BPH | RNA degradation | 29/1718 | 79/8465 | 5.17e-04 | 2.67e-03 | 1.65e-03 | 29 |
hsa0301813 | Prostate | BPH | RNA degradation | 29/1718 | 79/8465 | 5.17e-04 | 2.67e-03 | 1.65e-03 | 29 |
hsa0301822 | Prostate | Tumor | RNA degradation | 30/1791 | 79/8465 | 4.48e-04 | 2.35e-03 | 1.46e-03 | 30 |
hsa0301832 | Prostate | Tumor | RNA degradation | 30/1791 | 79/8465 | 4.48e-04 | 2.35e-03 | 1.46e-03 | 30 |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
XRN2 | SNV | Missense_Mutation | c.310N>A | p.Gly104Arg | p.G104R | Q9H0D6 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-AO-A03L-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | cyclophosphamide | SD | |
XRN2 | SNV | Missense_Mutation | rs376273044 | c.1844N>A | p.Arg615Gln | p.R615Q | Q9H0D6 | protein_coding | tolerated(0.39) | benign(0.019) | TCGA-AO-A12D-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cyclophosphamide | SD |
XRN2 | SNV | Missense_Mutation | rs746894001 | c.1084N>T | p.Arg362Cys | p.R362C | Q9H0D6 | protein_coding | deleterious(0) | probably_damaging(0.994) | TCGA-D8-A1JJ-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicine | SD |
XRN2 | SNV | Missense_Mutation | c.2755N>G | p.Pro919Ala | p.P919A | Q9H0D6 | protein_coding | tolerated_low_confidence(0.65) | benign(0) | TCGA-C5-A1M8-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD | |
XRN2 | SNV | Missense_Mutation | novel | c.2285A>T | p.Glu762Val | p.E762V | Q9H0D6 | protein_coding | tolerated(0.06) | benign(0.156) | TCGA-MA-AA3Z-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
XRN2 | SNV | Missense_Mutation | c.322N>T | p.Arg108Cys | p.R108C | Q9H0D6 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-AA-3663-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD | |
XRN2 | SNV | Missense_Mutation | c.664N>T | p.Asp222Tyr | p.D222Y | Q9H0D6 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-AA-3977-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD | |
XRN2 | SNV | Missense_Mutation | novel | c.113C>T | p.Ala38Val | p.A38V | Q9H0D6 | protein_coding | tolerated(0.09) | benign(0.012) | TCGA-AA-3984-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
XRN2 | SNV | Missense_Mutation | rs377677641 | c.2377N>T | p.Arg793Trp | p.R793W | Q9H0D6 | protein_coding | deleterious(0) | possibly_damaging(0.613) | TCGA-AA-A01R-01 | Colorectum | colon adenocarcinoma | Male | <65 | III/IV | Chemotherapy | 5-fluorouracil | PD |
XRN2 | SNV | Missense_Mutation | rs753036714 | c.1843N>T | p.Arg615Trp | p.R615W | Q9H0D6 | protein_coding | deleterious(0.01) | probably_damaging(0.948) | TCGA-AM-5821-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
Page: 1 2 3 4 5 6 7 8 9 10 11 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |